Empirical Finance LLC Acquires 156 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Empirical Finance LLC boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,180 shares of the medical equipment provider’s stock after purchasing an additional 156 shares during the period. Empirical Finance LLC’s holdings in Zimmer Biomet were worth $775,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZBH. BLB&B Advisors LLC grew its position in Zimmer Biomet by 2.1% during the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after acquiring an additional 100 shares during the last quarter. Financial Advocates Investment Management grew its holdings in shares of Zimmer Biomet by 3.5% in the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares during the last quarter. M&R Capital Management Inc. increased its stake in shares of Zimmer Biomet by 14.1% in the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 105 shares during the period. Mill Creek Capital Advisors LLC boosted its position in Zimmer Biomet by 5.1% during the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 106 shares during the period. Finally, HB Wealth Management LLC grew its holdings in Zimmer Biomet by 2.8% in the 2nd quarter. HB Wealth Management LLC now owns 3,864 shares of the medical equipment provider’s stock worth $419,000 after acquiring an additional 107 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ZBH. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Robert W. Baird cut their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. UBS Group decreased their target price on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a report on Thursday, August 8th. Royal Bank of Canada lifted their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Finally, Canaccord Genuity Group reduced their price objective on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Stock Up 3.4 %

Shares of NYSE:ZBH opened at $112.54 on Friday. The stock has a fifty day simple moving average of $106.28 and a two-hundred day simple moving average of $110.04. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $22.40 billion, a price-to-earnings ratio of 21.40, a PEG ratio of 2.07 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.65 earnings per share. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date was Monday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.